Abstract
Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Keywords: Receptor, channel, patch clamp, kinetics
Current Neuropharmacology
Title: Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids
Volume: 8 Issue: 1
Author(s): Gustav Akk, Douglas F. Covey, Alex S. Evers, Steven Mennerick, Charles F. Zorumski and Joe Henry Steinbach
Affiliation:
Keywords: Receptor, channel, patch clamp, kinetics
Abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Export Options
About this article
Cite this article as:
Akk Gustav, Covey F. Douglas, Evers S. Alex, Mennerick Steven, Zorumski F. Charles and Steinbach Henry Joe, Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909458
DOI https://dx.doi.org/10.2174/157015910790909458 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Gender-Specific Relationship Between Uric Acid Levels and Prognosis After Cerebral Venous Thrombosis
Current Neurovascular Research Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Quantitative Enzymology
Current Enzyme Inhibition Healthspan and Longevity in Mammals: A Family Game for Cellular Organelles?
Current Pharmaceutical Design Mitochondrial Oxidative Stress and Heart Failure ∼Novel Pathophysiological Insight and Treatment Strategies∼
Current Cardiology Reviews Computational Analysis of TRAPPC9: Candidate Gene for Autosomal Recessive Non-Syndromic Mental Retardation
CNS & Neurological Disorders - Drug Targets Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthesis of New Peptide Derivatives of Galanthamine Designed for Prevention and Treatment of Alzheimer’s Disease
Protein & Peptide Letters Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets Inhibition of Amyloid Fibrillation of HEWL by 4-Methylcoumarin and 4-Methylthiocoumarin Derivatives
Current Pharmaceutical Biotechnology Xenobiotic and Non-Xenobiotic Interventions in the Microbiome Therapeutics
Current Drug Metabolism Adolescent Pornography Use: A Systematic Literature Review of Research Trends 2000-2017
Current Psychiatry Reviews Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Mif1: A Missing Link between the Unfolded Protein Response Pathway and ER-Associated Protein Degradation?
Current Protein & Peptide Science Cellular Senescence in Ageing, Age-Related Disease and Longevity
Current Vascular Pharmacology E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
Current Pharmaceutical Design Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice
Current Alzheimer Research